Emily M. Leproust Sells 1,726 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,726 shares of the business’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $41.68, for a total transaction of $71,939.68. Following the completion of the sale, the chief executive officer now directly owns 660,966 shares in the company, valued at approximately $27,549,062.88. This represents a 0.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Twist Bioscience Stock Performance

TWST opened at $44.94 on Tuesday. The company has a market cap of $2.68 billion, a price-to-earnings ratio of -13.30 and a beta of 2.15. The company’s fifty day moving average price is $45.42 and its two-hundred day moving average price is $45.31. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.75) EPS. On average, analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on TWST. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird boosted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.40.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new position in Twist Bioscience during the 4th quarter worth $58,000. Westwood Holdings Group Inc. bought a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $657,000. Teza Capital Management LLC bought a new position in Twist Bioscience in the 4th quarter valued at $204,000. Sherbrooke Park Advisers LLC bought a new position in Twist Bioscience during the fourth quarter valued at about $238,000. Finally, ProShare Advisors LLC raised its position in Twist Bioscience by 30.5% in the fourth quarter. ProShare Advisors LLC now owns 19,226 shares of the company’s stock worth $893,000 after acquiring an additional 4,488 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.